APA (7th ed.) Citation

AT, F., N, K., SK, V., JS, S., JM, K., RS, S., & KB, F. (2012). Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (London, England), 26(9), 1181. https://doi.org/10.1038/eye.2012.174

Chicago Style (17th ed.) Citation

AT, Fung, Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS, and Freund KB. "Pilot Study to Evaluate the Role of High-dose Ranibizumab 2.0 Mg in the Management of Neovascular Age-related Macular Degeneration in Patients with Persistent/recurrent Macular Fluid <30 Days Following Treatment with Intravitreal Anti-VEGF Therapy (the LAST Study)." Eye (London, England) 26, no. 9 (2012): 1181. https://doi.org/10.1038/eye.2012.174.

MLA (9th ed.) Citation

AT, Fung, et al. "Pilot Study to Evaluate the Role of High-dose Ranibizumab 2.0 Mg in the Management of Neovascular Age-related Macular Degeneration in Patients with Persistent/recurrent Macular Fluid <30 Days Following Treatment with Intravitreal Anti-VEGF Therapy (the LAST Study)." Eye (London, England), vol. 26, no. 9, 2012, p. 1181, https://doi.org/10.1038/eye.2012.174.